Sugi Predict

Sugi Predict / Compounds / SCHEMBL765896

SCHEMBL765896

SCHEMBL765896

CC(C)n1cc(-c2ccnc(NC(=O)[C@H]3CC[C@@H](O)CC3)c2)n(-c2ccc(F)cc2)c1=O

nearest known ligand 0.55

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 5/20 0.55
▸ MET P08581 1/20 0.55
▸ TYRO3 Q06418 1/20 0.55
▸ MERTK Q12866 3/20 0.51
▸ MAPK14 Q16539 11/20 0.48
▸ GSK3B P49841 8/20 0.48
▸ PIK3C3 Q8NEB9 3/20 0.47
▸ MAPK8 P45983 4/20 0.47
▸ MAPK10 P53779 4/20 0.47
▸ GSK3A P49840 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13060307 0.76 MET (0.48) AXLMETMAPK14GSK3BPIK3C3
SCHEMBL10273085 0.76 MET (0.48) AXLMETMAPK14GSK3BPIK3C3
SCHEMBL10273983 0.75 MET (0.43) AXLMETTYRO3MERTKMAPK14
SCHEMBL765550 0.75 AXL (0.42) AXLMETTYRO3MERTKMAPK14
SCHEMBL764233 0.75 MAPK14 (0.53) MAPK14GSK3BPIK3C3MAPK8MAPK10
SCHEMBL1555187 0.71 MAPK14 (0.57) MAPK14GSK3BMAPK8MAPK10GSK3A
SCHEMBL10273087 0.70 MAPK14 (0.55) MAPK14MAPK8MAPK10
SCHEMBL764217 0.70 MAPK14 (0.46) MAPK14GSK3BPIK3C3MAPK8MAPK10
SCHEMBL16105395 0.68 MAPK14 (0.56) MAPK14GSK3BMAPK8MAPK10GSK3A
SCHEMBL23843401 0.67 PIK3C3 (0.53) MAPK14GSK3BPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1439174-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-21 — — EP disclosed
US-7846933-B2 such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-07 — — US disclosed
US-7846933-B2 such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-07 — — US disclosed
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS KUBO AKIRA 2009-04-02 — — US disclosed
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS KUBO AKIRA 2009-04-02 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS OR10J3, NR4A3, NR3C2 AXL 3448/4885MET 1884/4885TYRO3 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.